4.5 Article

Demographic, multi-morbidity and genetic impact on myocardial involvement and its recovery from COVID-19: protocol design of COVID-HEART-a UK, multicentre, observational study

Journal

Publisher

BMC
DOI: 10.1186/s12968-021-00752-1

Keywords

COVID-19; Coronavirus; Cardiovascular magnetic resonance; Myocarditis; Myopericarditis; Myocardial infarction; myocardial injury; Myocardial inflammation; Myocardial repair; Cardiovascular disease

Funding

  1. National Institute for Health Research (NIHR)
  2. UK Research and Innovation (UKRI) COVID-19 Rapid Response Rolling Call [COV0254]
  3. University of Leeds, UK
  4. National Institutes of Health Research (NIHR) [COV0254] Funding Source: National Institutes of Health Research (NIHR)

Ask authors/readers for more resources

COVID-HEART is a study aiming to provide detailed characterization of cardiac involvement, repair, and recovery in relation to comorbidity, genetics, patient-reported QoL measures, and functional capacity in COVID-19 patients with elevated troponin.
Background Although coronavirus disease 2019 (COVID-19) is primarily a respiratory illness, myocardial injury is increasingly reported and associated with adverse outcomes. However, the pathophysiology, extent of myocardial injury and clinical significance remains unclear. Methods COVID-HEART is a UK, multicentre, prospective, observational, longitudinal cohort study of patients with confirmed COVID-19 and elevated troponin (sex-specific > 99th centile). Baseline assessment will be whilst recovering in-hospital or recently discharged, and include cardiovascular magnetic resonance (CMR) imaging, quality of life (QoL) assessments, electrocardiogram (ECG), serum biomarkers and genetics. Assessment at 6-months includes repeat CMR, QoL assessments and 6-min walk test (6MWT). The CMR protocol includes cine imaging, T1/T2 mapping, aortic distensibility, late gadolinium enhancement (LGE), and adenosine stress myocardial perfusion imaging in selected patients. The main objectives of the study are to: (1) characterise the extent and nature of myocardial involvement in COVID-19 patients with an elevated troponin, (2) assess how cardiac involvement and clinical outcome associate with recognised risk factors for mortality (age, sex, ethnicity and comorbidities) and genetic factors, (3) evaluate if differences in myocardial recovery at 6 months are dependent on demographics, genetics and comorbidities, (4) understand the impact of recovery status at 6 months on patient-reported QoL and functional capacity. Discussion COVID-HEART will provide detailed characterisation of cardiac involvement, and its repair and recovery in relation to comorbidity, genetics, patient-reported QoL measures and functional capacity. Clinical Trial registration: ISRCTN 58667920. Registered 04 August 2020.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available